The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups
This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.
Read More
Describing SMA Progression Over Time
May 15th 2025Panelists discuss how spinal muscular atrophy (SMA) progresses over time, affecting motor function differently in older patients vs infants, with experts noting the shift from traditional classification (types 1 to 4) to functional categories (nonsitters, sitters, walkers).
Watch
Biosimilar Pricing Strategies: Understanding High-WAC and Low-WAC Models
May 15th 2025Panelists discuss how biosimilar manufacturers offer both high-wholesale acquisition cost (WAC) and low-WAC product versions to navigate complex reimbursement landscapes, sharing their experiences with low-WAC options on formularies, defining private label agreements as strategies to improve biosimilar access across different patient populations, and examining the rationale behind PBMs' (pharmacy benefit managers) implementation of these agreements, including their specific components and benefits.
Watch
The Growing Market for Biosimilars
May 15th 2025Panelists discuss how the significant price increases in reference biologics over the past decade have created market opportunities for biosimilars while exploring barriers to their adoption, potential solutions for enhancing uptake, and successful institutional strategies for increasing biosimilar utilization.
Watch
Navigation and Clinician Payment Investments Enhance Colorectal Cancer Screening Benefits
Investing in patient navigation and clinician incentives ensures colorectal cancer screening completion, improves early detection, reduces disparities, achieves cost savings, and advances population health for all stakeholders.
Read More
Infant RSV Hospitalization Rates Drop in First Season With Widespread Preventive Product Use
May 14th 2025New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.
Read More
Airway Clearance Techniques and Antibiotics for Patients With Bronchiectasis
Panelists discuss how airway clearance devices and techniques, including chest physical therapy, active cycle breathing, exercise, hypertonic saline, and oscillatory positive expiratory pressure devices, are the mainstay of bronchiectasis management.
Watch
Common Causes of Bronchiectasis
Panelists discuss how evaluating potential causes of bronchiectasis is important despite many cases being idiopathic, as identifying treatable traits can lead to specific interventions, such as CFTR modulators for those with CF mutations or IgG supplementation.
Watch
The Role of Novel Targeted Therapies
May 13th 2025A panelist discusses how novel targeted therapies such as antibody-drug conjugates are rapidly evolving in gynecologic oncology, with multiple agents targeting different biomarkers in development, though optimal sequencing strategies remain to be determined.
Watch
Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer
May 13th 2025A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, recommending it as first-line therapy for folate receptor alpha–high tumors due to higher response rates when used earlier.
Watch
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
Economic Impact of IgA Nephropathy for Patients
May 12th 2025Panelists discuss how immunoglobulin A (IgA) nephropathy progression creates escalating economic burdens for patients through direct health care costs, lost productivity, increasing medication needs, and eventually the overwhelming financial impact of dialysis or transplantation.
Watch
Improving Clinician Awareness and Adoption of Molecular Testing
May 12th 2025A panelist discusses how guidelines from organizations like the National Comprehensive Cancer Network (NCCN) can improve clinician awareness and adoption of molecular testing in community oncology settings while acknowledging that some effective treatments work across patient populations without requiring biomarker stratification.
Watch
Applying Trial Data to Real-World Practice in ALK+ NSCLC
Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these collective data have changed perspectives on frontline therapies for ALK+ non–small cell lung cancer (NSCLC).
Watch
The Impact of Tumor Heterogeneity in Ovarian Cancer
May 12th 2025A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, newer approaches like liquid biopsies can provide a more comprehensive genetic profile of the entire tumor burden.
Watch
Choosing Wisely: Insights from an MAIC and eXalt3
Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in December 2024 influence frontline treatment selection for ALK+ non–small cell lung cancer (NSCLC).
Watch
Measuring Success in IgA Nephropathy in Clinical Practice
May 12th 2025Panelists discuss how treatment success in immunoglobulin A (IgA) nephropathy extends beyond clinical trial end points to encompass sustained proteinuria reduction, stable kidney function, symptom improvement, and enhanced quality of life metrics that matter to patients in real-world settings.
Watch
Global Analysis Sheds Light on Women’s Cancer Trends
May 11th 2025As National Women’s Health Week approaches, new global data highlighting projected rises in breast and ovarian cancer through 2050 is prompting renewed calls for gender-specific prevention strategies that address evolving health risks for women.
Read More
Health Outcomes Under Full-Risk Medicare Advantage vs Traditional Medicare
Physician groups under 2-sided risk–based Medicare Advantage provide care associated with higher quality and efficiency compared with care by these same groups under fee-for-service Medicare.
Read More